IDDF2018-ABS-0081 Gradually decreasing of serum hbcrag in real-world chronic hepatitis B patients receiving long-term nucleot(s)ide analogues-based therapy

• Published in: Gut Vol. 67; no. Suppl 2; p. A95
• Main Authors: Wang, Menglan, Chen, Enqiang, Tao, Chuanming, Liao, Juan, Zhou, Taoyou, Wang, Juan, Yan, Libo, Wu, Dongbo, Du, Lingyao, Tang, Hong
• Format: Journal Article
• Language: English
• Published: 01.06.2018
• ISSN: 0017-5749; 1468-3288
• DOI: 10.1136/gutjnl-2018-IDDFabstracts.204

BackgroundThis study aimed to investigate the detailed dynamics of qHBcrAg and influence factors of long-term qHBcrAg in a cohort of patients who had received over 8 years of continuous NAs therapy.MethodsThis was a retrospective study. All patients were recruited from our previous published study, who started therapy with NAs between 2007 and 2008. Serum HBsAg and HBcrAg levels were quantitatively measured at baseline, the sixth month and each year of follow-up, using the stored serum samples.ResultsAmong the 94 patients, serum qHBcrAg presented a gradually decreasing trend from baseline to year 8, either in HBeAg-negative or HBeAg-positive patients. Good correlation of qHBcrAg and qHBsAg was observed at baseline, but this correlation weakened remarkably during treatment. Serum qHBcrAg.ConclusionsSerum HBcrAg levels are varied during the course of antiviral therapy, and qHBcrAg may serve as a new important tool for the management of CHB.